Table 1 Univariate and multivariate regression analysis of the association between overall survival and clinical characteristics and key driver mutations in KRAS mutated PDAC patients from the TCGA cohort

From: Molecular characterization and prognostic implications of KRAS mutations in pancreatic cancer patients: insights from multi-cohort analysis

Characteristics

Total (N)

HR(95% CI) Univariate analysis

P-value Univariate analysis

HR(95% CI) Multivariate analysis

P-value Multivariate analysis

Age

116

1.019 (0.997–1.042)

0.087

1.015 (0.992–1.039)

0.195

Sex

116

    

Male

69

Reference

   

Female

47

1.093 (0.685–1.745)

0.708

  

AJCC Stage

116

    

Stage I

8

Reference

   

Stage II

101

1.114 (0.404–3.073)

0.834

  

Stage III

3

1.352 (0.245–7.456)

0.729

  

Stage IV

4

1.127 (0.251–5.067)

0.876

  

KRAS

116

    

G12V

33

Reference

 

Reference

 

G12D

48

1.748 (0.984–3.107)

0.057

1.715 (0.965–3.048)

0.066

G12R

25

1.062 (0.508–2.224)

0.872

1.070 (0.511–2.242)

0.858

Q61

8

2.954 (1.151–7.585)

0.024

2.712 (1.048–7.020)

0.040

other

2

5.574 (1.260–24.665)

0.024

4.906 (1.098–21.924)

0.037

TP53

116

    

Mut

90

Reference

   

Wild

26

0.688 (0.375–1.263)

0.227

  

CDKN2A

116

    

Mut

33

Reference

   

Wild

83

0.887 (0.527–1.493)

0.652

  

SMAD4

116

    

Mut

32

Reference

   

Wild

84

1.281 (0.750–2.189)

0.365

  

TMB

116

1.111 (0.734–1.682)

0.618

  

MSI

116

1.021 (0.853–1.222)

0.820

  
Back to article page